BeyondSpring (NASDAQ:BYSI) has been assigned a $52.00 price target by research analysts at Maxim Group in a research report issued on Thursday. The firm presently has a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 59.95% from the company’s previous close.
Other equities research analysts also recently issued reports about the stock. HC Wainwright set a $60.00 target price on shares of BeyondSpring and gave the stock a “buy” rating in a research report on Thursday, October 26th. Zacks Investment Research downgraded shares of BeyondSpring from a “hold” rating to a “sell” rating in a research report on Monday, November 13th.
BeyondSpring (BYSI) traded down $1.30 on Thursday, reaching $32.51. 432 shares of the company’s stock traded hands, compared to its average volume of 5,475. BeyondSpring has a 12-month low of $16.55 and a 12-month high of $48.49.
A hedge fund recently bought a new stake in BeyondSpring stock. Tanaka Capital Management Inc. acquired a new position in BeyondSpring Inc. (NASDAQ:BYSI) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring makes up about 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned about 0.10% of BeyondSpring as of its most recent SEC filing. Institutional investors own 1.22% of the company’s stock.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.